An overview of targeted treatments in cancer

Clinical Therapeutics

Volumn 25, Issue 8, 2003, Pages 2121-2137

  Abou Jawde, Rony ^a   Choueiri, Toni ^a,b   Alemany, Carlos ^b   Mekhail, Tarek ^b  

^a Department of Internal Medicine ^*  (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Cancer treatment; Cancer vaccine; Chemotherapy; Epidermal growth factor; Monoclonal antibodies; Tyrosine kinase

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; ANTHRACYCLINE; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; CANCER VACCINE; CETUXIMAB; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; GEFITINIB; GEMTUZUMAB OZOGAMICIN; IMATINIB; INTERLEUKIN 2; PREDNISONE; RETINOIC ACID; RITUXIMAB; TRASTUZUMAB; VINCRISTINE;

ACUTE MYELOBLASTIC LEUKEMIA; ANGIONEUROTIC EDEMA; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; BREAST CANCER; BRONCHOSPASM; CANCER THERAPY; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DENDRITIC CELL; DIARRHEA; DRUG FATALITY; DRUG INDICATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; EDEMA; FATIGUE; FEVER; HEADACHE; HEART DISEASE; HUMAN; HYPOTENSION; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MYALGIA; NAUSEA; NONHODGKIN LYMPHOMA; OPPORTUNISTIC INFECTION; PROMYELOCYTIC LEUKEMIA; PRURITUS; PUBLICATION; RETINOIC ACID SYNDROME; REVIEW; SOLID TUMOR; TUMOR CELL; VACCINATION;

EID: 0042887615     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(03)80209-6     Document Type: Review

References (51)

1. Disis ML, Schiffman K. Issues on clinical applications of cancer vaccines. J Immunother. 2001;24:104-105.
2. Stone RM, Mayer RJ. The unique aspects of acute promyelocytic leukemia. J Clin Oncol. 1990;8:1913-1921.
3. Warrell RP Jr, de The H, Wang ZY, Degos L. Acute promyelocytic leukemia. N Engl J Med. 1993;329:177-189.
4. Rowley JD, Golomb HM, Dougherty C. 15/17 Translocation, a consistent chromosomal change in acute promyelocytic leukaemia. Lancet. 1977;1:549-550. Letter.
5. Mattei MG, Petrovich M, Mattei JF, et al. Mapping of the human retinoic acid receptor to the q21 band of chromosome 17. Hum Genet. 1988;80:186-188.
6. Daniel MT, Koken M, Romagne O, et al. PML protein expression in hematopoietic and acute promyelocytic leukemia cells. Blood. 1993;82:1858-1867.
7. Fenaux P, Degos L. Differentiation therapy for acute promyelocytic leukemia. N Engl J Med. 1997;337:1076-1077.
8. Tallman MS, Andersen JW, Schiffer CA, et al. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med. 1997;337:1021-1028.
9. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031-1037.
10. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001;344:1038-1042.
11. Goldman JM, Melo JV. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1084-1086.
12. O'Brien SG, Guilhot F, Larsen RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994-1004.
13. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003;348:1201-1214.
14. Dagher R, Cohen M, Williams G, et al. Approval summary: Imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res. 2002;8:3034-3038.
15. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256:495-497.
16. Weiner LM. An overview of monoclonal antibody therapy of cancer. Semin Oncol. 1999;26(Suppl 12):41-50.
17. Hernandez JA, Land KJ, McKenna RW. Leukemias, myeloma, and other lymphoreticular neoplasms. Cancer. 1995;75(Suppl 1):381-394.
18. Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2003. Cancer J Clin. 2003;53:5-26.
19. Dinndorf PA, Andrews RG, Benjamin D, et al. Expression of normal myeloid-associated antigens by acute leukemia cells. Blood. 1986;67:1048-1053.
20. Naito K, Takeshita A, Shigeno K, et al. Calicheamicin-conjugated humanized antiCD33 monoclonal antibody (gemtuzumab ozogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines. Leukemia. 2000;14:1436-1443.
21. Anderson KC, Bates MP, Slaughenhoupt BL, et al. Expression of human B cell-associated antigens on leukemias and lymphomas: A model of human B cell differentiation. Blood. 1984;63:1424-1433.
22. Einfeld DA, Brown JP, Valentine MA, et al. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J. 1988;7:711-717.
23. Press OW, Appelbaum F, Ledbetter JA, et al. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood. 1987;69:584-591.
24. White CA, Weaver RL, Grillo-Lopez AJ. Antibody-targeted immunotherapy for treatment of malignancy. Annu Rev Med. 2001;52:125-145.
25. Press OW. Radiolabeled antibody therapy of B-cell lymphomas. Semin Oncol. 1999;26(Suppl 14):58-65.
26. Ferrajoli A, O'Brien S, Keating MJ. Alemtuzumab: A novel monoclonal antibody. Expert Opin Biol Ther. 2001;1:1059-1065.
27. Dyer MJ. The role of CAMPATH-1 antibodies in the treatment of lymphoid malignancies. Semin Oncol. 1999;26(Suppl 14):52-57.
28. Morrison VA. Update on prophylaxis and therapy of infection in patients with chronic lymphocytic leukemia. Expert Rev Anticancer Ther. 2001;1:84-90.
29. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995;19:183-232.
30. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2000;103:211-225.
31. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792.
32. Toikkanen S, Helin H, Isola J, Joensuu H. Prognostic significance of HER-2 oncoprotein expression in breast cancer: A 30-year follow-up. J Clin Oncol. 1992;10:1044-1048.
33. Harari D, Yarden Y. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene. 2000;19:6102-6114.
34. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20:719-726.
35. Osoba D, Slamon DJ, Burchmore M, et al. Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer. J Clin Oncol. 2002;20:3106-3113.
36. Waksal HW. Role of an anti-epidermal growth factor receptor in treating cancer. Cancer Metastasis Rev. 1999;18:427-436.
37. O'dwyer PJ, Benson AB III. Epidermal growth factor receptor-targeted therapy in colorectal cancer. Semin Oncol. 2002;29(Suppl 14):10-17.
38. Xiong HQ, Abbruzzese JL. Epidermal growth factor receptor-targeted therapy for pancreatic cancer. Semin Oncol. 2002;29(Suppl 14):31-37.
39. Bunn PA Jr, Franklin W. Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer. Semin Oncol. 2002;29(Suppl 14):38-44.
40. Huang SM, Li J, Harari PM. Molecular inhibition of angiogenesis and metastatic potential in human squamous cell carcinomas after epidermal growth factor receptor blockade. Mol Cancer Ther. 2002;1:507-514.
41. Needle MN. Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibody. Semin Oncol. 2002;29(Suppl 14):55-60.
42. Herbst RS. Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients. Semin Oncol. 2003;30(Suppl 1):30-38.
43. Wiemann B, Starnes CO. Coley's toxins, tumor necrosis factor and cancer research: A historical perspective. Pharmacol Ther. 1994;64:529-564.
44. Boon T, Coulie PG, Van den Eynde B. Tumor antigens recognized by T cells. Immunol Today. 1997;18:267-268.
45. Fyfe G, Fisher RI, Rosenberg SA, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995;13:688-696.
46. Rosenberg SA, Yang JC, White DE, Steinberg SM. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: Identification of the antigens mediating response. Ann Surg. 1998;228:307-319.
47. Phan GQ, Wang E, Marincola FM. T-cell-directed cancer vaccines: Mechanisms of immune escape and immune tolerance. Expert Opin Biol Ther. 2001;1:511-523.
48. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med. 1998;4:328-332.
49. Vermorken JB, Claessen AM, van Tinteren H, et al. Active specific immunotherapy for stage II and stage III human colon cancer: A randomised trial. Lancet. 1999;353:345-350.
50. Harris JE, Ryan L, Hoover HC Jr, et al. Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283. J Clin Oncol. 2000;18:148-157.
51. Kugler A, Stuhler G, Walden P, et al. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med. 2000;6:332-336.